Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the first quarter, the U.S. equity market declined, with the S&P 500 Index falling by 4.33%. The fixed-income sector also saw a downturn; the Bloomberg U.S. Aggregate Bond Index fell by 0.05%. In the quarter, the Fund (Class I-2) posted a total return of -4.45%, compared to the S&P 500 Index’s -4.33% return. The Fund’s underperformance in the quarter was driven by the allocation effect, while security selection contributed positively. In this environment, the Fund continues to focus on companies experiencing secular tailwinds or robust product-driven cycles. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Aristotle Core Equity Fund highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is a medical technology company that manufactures and markets medical devices for use in various interventional medical specialties. On May 13, 2026, Boston Scientific Corporation (NYSE:BSX) closed at $53.06 per share. One-month return of Boston Scientific Corporation (NYSE:BSX) was -16.34%, and its shares lost 49.40% over the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a market capitalization of $78.87 billion.
Aristotle Core Equity Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2026 investor letter:
“Boston Scientific Corporation (NYSE:BSX) detracted from performance in the first quarter as investors debated the durability of the outsized growth the company has reported in electrophysiology (EP) and the Watchman left atrial appendage closure device. Boston reported positive results toward the end of the quarter on the CHAMPION-AF trial comparing the Watchman device to standard blood-thinner treatment in stroke prevention; however, the results still fell short of market expectations. Boston will need to show a rebound in EP results when it reports first quarter earnings to quell market concerns.”
Boston Scientific Corporation (NYSE:BSX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 110 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the fourth quarter, up from 102 in the previous quarter. In the first quarter of 2026, Boston Scientific Corporation (NYSE:BSX) delivered consolidated revenue of $5.203 billion, representing 11.6% year-over-year growth compared to Q1 2025. While we acknowledge the risk and potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Boston Scientific Corporation (NYSE:BSX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of stocks on which Jim Cramer commented on. Polen Focus Growth Strategy sold its stake in Boston Scientific Corporation (NYSE:BSX) in Q1 2026 due to concerns over increasing competition. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
